During the 23rd Congress of the Hellenic Heart Failure Society we presented our experience on use of Sacubitril/Valsartan in heart failure. The congress took place in Athens on 4-6 February 2022.
Through the presentation we have shown that the use of the medication was feasible and safe in real world conditions. This is particularly important for countries with high temperatures such as Cyprus, where the risk of hypotension from heart failure medications is high.
We have also shown that there was clinical and echocardiographic benefit even in people who were not able to receive the maximum dosage of the drug.
